M
Min Yao
Researcher at University Hospitals of Cleveland
Publications - 129
Citations - 4080
Min Yao is an academic researcher from University Hospitals of Cleveland. The author has contributed to research in topics: Head and neck cancer & Radiation therapy. The author has an hindex of 30, co-authored 122 publications receiving 3165 citations. Previous affiliations of Min Yao include Case Western Reserve University & University of Iowa.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Maura L. Gillison,Andy Trotti,Jonathan Harris,Avraham Eisbruch,Paul M. Harari,David J. Adelstein,Richard C.K. Jordan,Weiqiang Zhao,Erich M. Sturgis,Barbara Burtness,John A. Ridge,Jolie Ringash,James M. Galvin,Min Yao,Shlomo A. Koyfman,Dukagjin Blakaj,Mohammed A. Razaq,A. Dimitrios Colevas,Jonathan J. Beitler,Christopher U. Jones,Neal Dunlap,Samantha A. Seaward,Sharon A. Spencer,Thomas J. Galloway,Jack Phan,James J. Dignam,James J. Dignam,Quynh-Thu Le +27 more
TL;DR: After median follow-up duration of 4·5 years, radiotherapy plus cetuximab did not meet the non-inferiority criteria for overall survival, and patients were stratified by T category (T1-T2 vs T3-T4), N category (N0-N2a vs N2b-N3), Zubrod performance status (0 vs 1), and tobacco smoking history (≤10 pack-years).
Journal ArticleDOI
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.
Vincent Grégoire,Mererid Evans,Quynh-Thu Le,Jean Bourhis,Volker Budach,Amy Chen,Abraham Eisbruch,Mei Feng,Jordi Giralt,Tejpal Gupta,Marc Hamoir,Juliana K. Helito,Chaosu Hu,Keith D. Hunter,Jørgen Johansen,Johannes H.A.M. Kaanders,Sarbani Ghosh Laskar,Anne W.M. Lee,Philippe Maingon,Antti Mäkitie,Francesco Miccichè,Piero Nicolai,Brian O'Sullivan,Adela Poitevin,Sandro V. Porceddu,Krzysztof Składowski,Silke Tribius,John Waldron,Joseph Wee,Min Yao,Sue S. Yom,Frank Zimmermann,Cai Grau +32 more
TL;DR: In this article, the authors proposed two clinical target volume (CTV) guidelines for head and neck squamous cell carcinoma, namely CTV-P1 and CVT-P2, which are associated with a high and lower tumour burden, respectively.
Journal ArticleDOI
Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma - The University of Iowa experience
Min Yao,Kenneth J. Dornfeld,John M. Buatti,Mark Skwarchuk,Huaming Tan,Thanh X. Nguyen,Judith Wacha,John E. Bayouth,Gerry F. Funk,Russell B. Smith,Scott M. Graham,Kristi E. Chang,Henry T. Hoffman +12 more
TL;DR: The results have confirmed the effectiveness of IMRT in head-and-neck cancer and offers excellent outcomes in local-regional control and overall survival.
Journal ArticleDOI
The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment
Min Yao,Russell B. Smith,Michael M. Graham,Henry T. Hoffman,Huaming Tan,Gerry F. Funk,Scott M. Graham,Kristi E. Chang,Kenneth J. Dornfeld,Yusuf Menda,John M. Buatti +10 more
TL;DR: For patients who have no evidence of residual lymphadenopathy and a negative FDG PET scan 12 weeks after definitive radiation, neck dissection can be safely withheld, and further studies with longer follow-up are necessary to determine the appropriateness of withholding neck dissections.
Journal ArticleDOI
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
Sue S. Yom,Pedro A. Torres-Saavedra,Jimmy J. Caudell,John Waldron,Maura L. Gillison,Ping Xia,Minh Tam Truong,Christina S. Kong,Richard C.K. Jordan,Rathan M. Subramaniam,Min Yao,Christine H. Chung,Jessica L. Geiger,Jason Chan,Brian O'Sullivan,Dukagjin Blakaj,Loren K. Mell,Wade L. Thorstad,Christopher U. Jones,Robyn Banerjee,C.E. Lominska,Quynh-Thu Le +21 more
TL;DR: In this article, the quality of life (QOL) of patients with good-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma (OPSCC) was evaluated.